EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling

Noora Sjöstedt iD, Ogochukwu U Amaeze iD, Jeroen J M W van den Heuvel, Tore B Stage iD, Jan B Koenderink, Nina Isoherranen iD, Heidi Kidron iD, Erkka Järvinen iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Noora Sjöstedt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Floxacillin, Organic Anion Transporters, Dicloxacillin, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dicloxacillin and flucloxacillin are β‐lactamase‐resistant penicillin antibiotics that have been in clinical use for over 50 years. While both antibiotics are known to induce cytochrome P450 enzymes, there is limited information available regarding their interactions with drug transporters. Here, we investigated the in vitro transport and inhibition of hepatic organic anion transporting polypeptides (OATPs) and renal organic anion transporters (OATs) by these antibiotics in recombinant transporter overexpressing HEK293 cells. We also investigated the transport of these antibiotics by efflux transporters, as well as their inhibition of breast cancer resistance protein (BCRP) and P‐glycoprotein (P‐gp) using a HEK293 membrane vesicle transport assay. Dicloxacillin and flucloxacillin inhibited rosuvastatin transport by OATP1B1, OATP1B3, and OATP2B1, and the inhibition was strongest for OATP1Bs with IC 50 values of 3.9 and 31 μM (OATP1B1) and 6.7 and 21 μM (OATP1B3) for dicloxacillin and flucloxacillin, respectively. Both antibiotics also inhibited BCRP‐mediated rosuvastatin transport with IC 50 values of 166 μM (dicloxacillin) and 379 μM (flucloxacillin), while P‐gp‐mediated transport of N‐methyl‐quinidine was inhibited to a lesser extent. All OATPs and OATs transported dicloxacillin and flucloxacillin. Static model predictions indicated that the inhibition of OATPs, BCRP, and P‐glycoprotein by both compounds may be clinically relevant. We further developed and verified physiologically based pharmacokinetic (PBPK) models for dicloxacillin and flucloxacillin. PBPK model simulations predicted no major change in rosuvastatin, a substrate for OATPs and BCRP, pharmacokinetics when co‐administered with dicloxacillin or flucloxacillin. Simulations with dicloxacillin and P‐gp substrates dabigatran or digoxin also predicted limited inhibition of P‐gp transport.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FloxacillinOrganic Anion TransportersDicloxacillinLiverAnti-Bacterial AgentsHumansHEK293 CellsRosuvastatin CalciumModels, BiologicalATP Binding Cassette Transporter, Subfamily G, Member 2Biological TransportNeoplasm ProteinsLiver-Specific Organic Anion Transporter 1Solute Carrier Organic Anion Transporter Family Member 1B3Drug Interactions

Stichwörter der Autor:innen

DDIPBPKantibioticsdrug–drug interactionin silicoin vitroinhibitiontransporter

Substanzen

FloxacillinOrganic Anion TransportersRosuvastatin CalciumDicloxacillinAnti-Bacterial AgentsATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsLiver-Specific Organic Anion Transporter 1ABCG2 protein, humanSLCO1B1 protein, human

Autor:innen und Institutionen

  • Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
  • Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Noora Sjöstedt, Ogochukwu U Amaeze, Tore B Stage, Nina Isoherranen, Heidi Kidron, Erkka Järvinen

Zitieren

APA

Sjöstedt, N., Amaeze, O. U., van den Heuvel, J. J. M. W., Stage, T. B., Koenderink, J. B., Isoherranen, N., Kidron, H., & Järvinen, E. (2026). Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. Clinical and Translational Science. https://doi.org/10.1111/cts.70487

Vancouver

Sjöstedt N, Amaeze OU, van den Heuvel JJMW, Stage TB, Koenderink JB, Isoherranen N, et al. Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. Clinical and Translational Science. 2026. doi:10.1111/cts.70487

BibTeX
@article{Sjstedt2026,
  author = {Sjöstedt, Noora and Amaeze, Ogochukwu U and van den Heuvel, Jeroen J M W and Stage, Tore B and Koenderink, Jan B and Isoherranen, Nina and Kidron, Heidi and Järvinen, Erkka},
  title = {Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70487}
}
Kostenlos starten →